Business Context and Reporting Period
This Form 8-K, dated January 24, 2024, is filed by Semper Paratus Acquisition Corporation (the "Registrant"). The filing discloses a material update regarding the proposed business combination with Tevogen Bio Inc. ("Tevogen Bio"). Upon closing, Semper Paratus will redomesticate from the Cayman Islands to Delaware, change its name to Tevogen Bio Holdings Inc., and merge with Tevogen Bio.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either Semper Paratus or Tevogen Bio. This report focuses on corporate governance and transactional updates rather than financial performance data.
Material Changes
- Listing Venue Change: The parties have agreed to seek to list the combined company's common stock and public warrants on a tier of The Nasdaq Stock Market instead of the NYSE American, as previously disclosed in the Proxy Statement/Prospectus dated January 10, 2024.
- Prospectus Supplement: A supplement to the definitive proxy statement/prospectus has been filed to reflect the change in listing venue.
- Shareholder Vote: An extraordinary general meeting of Semper Paratus shareholders is scheduled for January 29, 2024, to vote on the Business Combination.
Outlook, Risks, and Contingencies
Management commentary is limited to the announcement of the listing venue change. The filing contains extensive forward-looking statements regarding the anticipated benefits, timing, and financial condition of the combined company, which are subject to significant risks.
Key Risks and Contingencies:
- Transaction Completion: Risk that the Business Combination may not be completed by the deadline or at all.
- Redemptions: Risk that shareholder redemptions may exceed anticipated levels, potentially failing to meet minimum cash requirements at closing.
- Listing Standards: Risk of failing to meet Nasdaq initial listing standards.
- Capital Needs: Risk that Tevogen Bio may need to raise additional capital to execute its business plan, which may not be available on acceptable terms.
- Operational Risks: Risks related to clinical trials, regulatory approvals, intellectual property, and the limited operating history of Tevogen Bio.
Investor Verification Checklist
- Verify the final listing venue (Nasdaq) and associated listing standards in the updated Prospectus Supplement.
- Review the Proxy Statement/Prospectus for details on the Merger Agreement, including the implied enterprise value and exchange ratios.
- Confirm the outcome of the shareholder vote scheduled for January 29, 2024.
- Assess the level of shareholder redemptions and the resulting cash position at closing.
- Examine Tevogen Bio's pipeline status, regulatory risks, and capital requirements in the Form S-4.